Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Eesti - eesti - Ravimiamet

hankintatukku oy - hõlmikpuulehed - suukaudsed tilgad, lahus - 910mg 1ml 100ml 1tk; 910mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

viatris sia - trandolapriil - kõvakapsel - 2mg 98tk; 2mg 28tk; 2mg 50tk; 2mg 60tk; 2mg 100tk

Eesti - eesti - Ravimiamet

viatris sia - trandolapriil - kõvakapsel - 4mg 56tk; 4mg 98tk; 4mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatoniin - sleep initiation and maintenance disorders; autistic disorder - psühhoeptikumid - slenyto on näidustatud ravi unetust lastel ja noorukitel vanuses 2-18 autismi spektri häire (asd) ja / või smith-magenis sündroomi, kus une hügieeni meetmed on ebapiisavad,.

Euroopa Liit - eesti - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic häired - südame teraapia - namuscla on näidustatud sümptomaatiline ravi myotonia täiskasvanud patsientidel, kellel on mitte-huumustoiteline myotonic häired.

Eesti - eesti - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 14tk; 10mg 98tk; 10mg 20tk; 10mg 56tk; 10mg 90tk

Eesti - eesti - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 40mg 20tk; 40mg 30tk; 40mg 56tk; 40mg 84tk; 40mg 90tk

Eesti - eesti - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 20tk; 20mg 28tk; 20mg 98tk; 20mg 90tk; 20mg 30tk; 20mg 56tk; 20mg 84tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatiit, atoopiline - muud dermatoloogilised preparaadid - staquis on näidustatud kerge kuni mõõduka atoopiline dermatiit täiskasvanud ja pediaatriliste patsientide alates 2 aasta vanusest, kellel ≤ 40% keha pinnast (bsa) mõjutatud.